Table 2.
Factors associated with PI-based second-line regimen success at time of inclusion (N = 1,281).
| Viral load (VL) failure (N = 135) | VL success (N = 1,182) | Univariate OR (95% CI) | p Overall | Multivariate OR (95% CI)N = 1,281 | p Overall | |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Female | 48 (35.6) | 468 (39.6) | 1 | 1 | ||
| Male | 87 (64.4) | 714 (60.4) | 0.84 (0.58–1.22) | 0.36 | 0.93 (0.62–1.41) | 0.76 |
| Age (years)a | ||||||
| Age, Median (IQR) | 42 (35–48) | 42 (38–48) | 0.10 | 0.34 | ||
| Baseline CD4 (cells per µL)b | ||||||
| Mediane, IQR | 360 (165–492) | 517 (376–688) | <0.0001 | |||
| <200 | 40 (29.9) | 59 (5) | 1 | 1 | ||
| 201–350 | 25 (18.7) | 197 (16.8) | 5.34 (3–9.52) | <0.0001 | 4.66 (2.57–8.47) | <0.0001 |
| >350 | 69 (51.5) | 917 (78.2) | 9.01 (5.63–14.42) | <0.0001 | 6.67 (4.02–11.06) | <0.0001 |
| Duration of PI-based regimen (years) | ||||||
| Mediane, IQR | 3.88 (1.57–6.19) | 5.08 (2.88–6.70) | 0.0001 | |||
| <2 | 40 (29.6) | 164 (13.9) | 1 | 1 | ||
| >2 | 95 (70.4) | 1,018 (86.1) | 2.61 (1.74–3.92) | <0.0001 | 1.64 (1.03–2.62) | 0.037 |
| Second-line regimenc | ||||||
| LPV | 35 (25.9) | 158 (13.5) | 1 | 1 | ||
| ATV | 97 (71.9) | 993 (84.8) | 2.27 (1.49–3.46) | 0.0014 | 1.63 (1.02–2.59) | 0.039 |
| ATV + LPV | 3 (2.2) | 20 (1.7) | 1.48 (0.41–5.24) | 0.55 | 1.26 (0.33–4.77) | 0.74 |
| Adherence level | ||||||
| Low adherence | 11 (8.1) | 30 (2.6) | 1 | 1 | ||
| Mod adherence | 17 (12.6) | 161 (13.6) | 3.47 (1.48–8.14) | 0.004 | 2.37 (0.92–6.10) | 0.073 |
| High adherence | 107 (79.3) | 990 (83.8) | 3.39 (1.65–6.96) | 0.001 | 2.41 (1.07–5.41) | 0.033 |
aN = 1,304.
bN = 1,307.
cN = 1,306.
Significant p value are in bold font.